A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

To join this study, you must be at least 18 years old and have a confirmed diagnosis of extensive stage small-cell lung cancer. Your cancer must be measurable, meaning doctors can track its size. Your doctors must also believe you are well enough to receive the treatments involved in the study, and you should be expected to live for at least 12 weeks.

There are also some reasons why you might not be able to join. For example, if you've had another type of cancer in the last two years, or if your lung cancer has spread to your brain causing symptoms. You also can't take part if you've had severe allergic reactions to similar treatments before, or if you've recently had a stroke or certain heart problems.

Other reasons that might prevent participation include having active autoimmune disease, certain infections like HIV or Hepatitis, serious lung conditions (like interstitial lung disease), or if you've had an organ transplant. The study team will carefully check all these points to ensure the study is safe for you.

If you decide to take part in this study, you will be assigned to one of two treatment groups, like flipping a coin. You will receive either the standard treatment combination (durvalumab, carboplatin, and etoposide) or the new combination (adding tarlatamab to those three drugs). You will have regular visits to the clinic for your treatments, which are usually given through an IV (a drip into your arm).

During these visits, doctors and nurses will closely monitor your health, check for any side effects, and perform tests like blood tests and scans to see how you are responding to the treatment. The exact number and timing of visits, tests, and how long you receive treatment will be explained in detail by the study team. After your treatment period, you will have follow-up visits to continue monitoring your health and how you are doing in the long term. The total time you spend in the study, from your first dose to the final follow-up, can vary.